Bifogade filer
PDF
Kurs
-10,11%
Likviditet
0,37 MSEK
Kalender
| Est. tid* | ||
| 2026-06-11 | N/A | Årsstämma |
| 2026-05-11 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-27 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-21 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-29 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-24 | - | Årsstämma |
| 2025-05-19 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2025-05-16 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-08 | - | Extra Bolagsstämma 2025 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-20 | - | Kvartalsrapport 2024-Q3 |
| 2024-09-04 | - | Extra Bolagsstämma 2024 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-22 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2023-05-12 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-08 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2022-05-23 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-06 | - | Årsstämma |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-11-24 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-22 | - | Extra Bolagsstämma 2021 |
| 2021-06-09 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2021-06-08 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | Extra Bolagsstämma 2020 |
| 2020-05-13 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2020-05-12 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-22 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-10 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-12-13 | - | Extra Bolagsstämma 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2018-05-23 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-28 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Inhalation Sciences Sweden AB (publ) has received several new Inhalation Research Service (IRS) orders from recurring global pharmaceutical companies with a total value of approximately EUR 52,000 (approximately SEK 554,000).
The orders relate to the company's technology platform PreciseInhale® and DissolvIt® designed to deliver controlled and high-precision inhalation exposures for preclinical research.
"These orders confirm a continued strong interest in our technology from our existing customer base and leading pharmaceutical companies", says Manoush Masarrat, CEO of Inhalation Sciences.
"We see increased client activity as more companies discover the benefits of our unique technology platform, particularly considering a changing regulatory landscape where more precise, efficient and cost-effective inhalation testing methods are needed. Our solutions enable significant time and cost savings while improving data quality, which is becoming increasingly important for drug development."
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.